欢迎访问厦门大学生命科学学院官方网站

黄佳良教授博导

发布时间:2016-01-17来源:生命科学学院点击数:8863

             


黄佳良  HUANG Jialiang, Ph.D.

教授,博士生导师

闽江学者特聘教授

生物信息学与表观基因组学(Bioinformatics and Epigenomics)

课题组长

E-mail:jhuang@xmu.edu.cn

2005年,福州大学,生物工程学士

2008年,福州大学,计算机软件与理论硕士

2012年,中国科学院遗传与发育生物学研究所,生物信息学博士

2011-2013,葛兰素史克上海医药研发有限公司,科学家

2013-2018,哈佛大学Dana-Farber癌症研究所/波士顿儿童医院,博士后

2018年至今,厦门大学生命科学学院,闽江学者特聘教授

  

2005, B.Sc., Fuzhou University

2008, M.Sc., Fuzhou University

2012, Ph.D., Chinese Academy of Science

2011-2013, Scientist, GlaxoSmithKline (China) R&D Co., Ltd., Shanghai

2013-2018, Postdoc, Dana-Farber Cancer Institute/Boston Children's Hospital, Harvard Medical School

2018-present, Principal Investigator, School of Life Sciences, Xiamen University

  

研究领域Research Area

本课题组利用生物信息学(干)和分子生物学(湿)等方法,研究哺乳动物发育和癌症发生的表观遗传调控机制。(1)设计生物信息学算法,解决生物组学数据分析的定量问题,例如scRNA-seq、ATAC-seq、HiC及ChIP-seq等;(2)整合表观基因组学数据,构建血液发育过程中的增强子动态调控网络,寻找关键调控因子或元件;(3)利用单细胞组学和表观基因组学等技术,探索癌症发生和治疗相关的细胞异质性及基因调控网络,寻找潜在药物靶标。  

We are interest in understanding the epigenetic regulation mechanisms of development and cancer using computational (dry) and experimental (wet) methods. Our current research includes: (1) developing computational methods for quantification problems for various omics data, such as scRNA-seq, HiC, ATAC-seq and ChIP-seq; (2) integrating genomic, transcriptomic, and epigenomic data to elucidate the gene regulatory networks and for blood development; (3) using single-cell analysis and epigenetic approaches to investigate the cellular heterogeneity and gene regulatory mechanisms associated with cancer progression and treatment response, which helps to identify potential drug targets.

本课题组热诚欢迎具有分子生物学、数理统计和计算机编程等交叉学科基础的硕士生、博士生、博士后和助理教授加盟!


代表性论文Selected Publications 

1.J. Huang#, K. Li#, W. Cai, X. Liu, Y. Zhang, S. H. Orkin, J. Xu, G.-C. Yuan. Dissecting super-enhancer hierarchy based on chromatin interactions. Nat Commun, 9: 943, 2018. (#Equal contribution)

2.E. Marco#, W. Meuleman#, J. Huang#, K. Glass, L. Pinello, J. Wang, M. Kellis, G.-C. Yuan. Multi-scale chromatin state annotation using a hierarchical hidden Markov model. Nat Commun, 8: 15011, 2017.

3.J. Huang#, X. Liu#, D. Li#, Z. Shao#, H. Cao, Y. Zhang, E. Trompouki, T. V. Bowman, L. I. Zon, G.-C. Yuan, S. H. Orkin, J. Xu. Dynamic control of enhancer repertoires drives lineage and stage-specific transcription during hematopoiesis. Dev Cell, 36: 9-23, 2016.

4.J. Huang, E. Marco, L. Pinello, G.-C. Yuan. Predicting chromatin organization using histone marks. Genome Biol, 16: 162, 2015.

5.J. Huang, C. Niu, C. D.Green, L. Yang, H. Mei, J.-D. J. Han. Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network. PLoS Comput Biol, 9: e1002998, 2013.

6.J. Huang, Y. Liu, W. Zhang, H. Yu and J.-D. J. Han. eResponseNet: a package prioritizing candidate disease genes through cellular pathways. Bioinformatics, 27: 2319-2320, 2011.

7.H. Xie, C. Peng, J. Huang, B. Li, W. Kim, E. Smith, Y. Fujiwara, J. Qi, G. Cheloni, P. P. Das, M. Nguyen, S. Li, J. E. Bradner, S. H. Orkin. Chronic myelogenous leukemia initiating cells require Polycomb group protein EZH2. Cancer Discov, 6: 1237-1247, 2016.

8.J. Xu#, Z. Shao#, D. Li, H. Xie, W. Kim, J. Huang, J. E. Taylor, L. Pinello, K. Glass, J. D. Jaffe, G.-C. Yuan, S. H. Orkin. Developmental control of polycomb subunit composition by GATA factors mediates a switch to  non-canonical functions. Mol Cell, 57: 304-316, 2015. 

9.S. Beyaz#, J. Kim#, L. Pinello#, Y. Hu, M. A. Kerenyi, P. P. Das, R. A. Barnitz, M. E. Xifaras, R. Dogum, J. Huang, W. N. Haining, O. Yilmaz, G.-C. Yuan, S. H. Orkin*, F. Winau*. The histone demethylase UTX regulates the lineage-specific epigenetic program of invariant natural killer T cells. Nature Immunology. 2017; 18, 184-195.